Science Catalysts And Exit Opportunities Will Support A Stronger Long Term Outlook

Catalysts

About IP Group

IP Group backs science based businesses from universities and research ecosystems, using its own balance sheet and third party capital to support them from early stages through scale up.

What are the underlying business or industry changes driving this perspective?

• The reopening of U.S. IPO and health tech listing activity, illustrated by Hinge Health, is giving IP Group more routes to realise holdings. This directly affects cash generation and the timing of any uplift or crystallisation in earnings from exits.
• Growing interest from pension schemes and public entities in private market and U.K. science exposure, including initiatives like the Mansion House commitments and new mandates targeted by IP Group, can expand fee earning assets under management and support group revenue and net income visibility.
• Increased public and private sector focus on areas such as health, medical science, generative biology, food security and sustainable agriculture aligns with Oxford Nanopore and similar holdings. This may support commercial traction and, if successful, contribute to revenue growth at portfolio level and NAV per share resilience for IP Group.
• Rising demand for climate and energy transition solutions, reflected in interest around sustainable aviation fuel and high efficiency hydrogen technologies in the portfolio, gives IP Group exposure to areas that can attract external funding and, if portfolio companies execute well, support higher exit proceeds and potential gains in earnings on disposal.
• Management’s emphasis on scaling private scale up capital, alongside Parkwalk’s university spin out channel, is intended to deepen funding for maturing assets. This can reduce dilution at portfolio company level and, if exits materialise as targeted, support NAV per share and cash proceeds available for buybacks.

Assumptions

How have these above catalysts been quantified?

• IP Group currently has no revenue. Analysts are forecasting revenue to reach £137.2 million by March 2029.
• As a pre-revenue company, Analysts expect IP Group to achieve a profit margin of 94.3% in 3 years time.
• Analysts expect earnings to reach £129.4 million (and earnings per share of £0.15) by about March 2029, up from -£135.7 million today.
• In order for the above numbers to justify the price target of the analysts, the company would need to trade at a PE ratio of 9.3x on those 2029 earnings, up from -3.3x today. This future PE is lower than the current PE for the GB Capital Markets industry at 14.0x.
• Analysts expect the number of shares outstanding to remain consistent over the next 3 years.
• To value all of this in today's terms, we will use a discount rate of 8.92%, as per the Simply Wall St company report.

Risks

What could happen that would invalidate this narrative?

• IP Group is targeting £250 million of exits by the end of 2027, but several portfolio companies, such as Oxa and others awaiting funding rounds or trial readouts, still depend on external capital and buyer interest. Any slowdown in private funding, M&A, or IPO activity could delay exits and reduce realised values, which would weigh on revenue from gains on disposal and on earnings.
• A meaningful part of the long term story rests on life sciences assets, including Istesso, Pulmocide, Artios and other clinical stage holdings. If clinical data, regulatory outcomes or future drug pricing rules in key markets like the U.S. are less favourable than management hopes, this could cap licensing opportunities and sale proceeds, putting pressure on both revenue potential and net margins.
• The push to grow scale up capital and win new third party mandates from pension schemes and public bodies has taken longer than management initially expected. If policy changes, competition from other managers or slower pension fund decision making limit new mandates, fee earning assets under management may expand more slowly than planned, which would constrain management fee growth and keep net overheads a larger drag on earnings.
• The investment case leans heavily on the perceived long term value in U.K. science and technology and on IP Group’s role in university spin outs. If U.K. university funding, tech transfer budgets or government backed schemes come under sustained financial pressure, the pipeline of attractive new companies could thin, reducing future portfolio refresh and making it harder to grow revenue and earnings beyond the current set of holdings.

Valuation

How have all the factors above been brought together to estimate a fair value?

• The analysts have a consensus price target of £1.01 for IP Group based on their expectations of its future earnings growth, profit margins and other risk factors.
  
• In order for you to agree with the analysts, you'd need to believe that by 2029, revenues will be £137.2 million, earnings will come to £129.4 million, and it would be trading on a PE ratio of 9.3x, assuming you use a discount rate of 8.9%.
  
• Given the current share price of £0.5, the analyst price target of £1.01 is 50.3% higher.
  
• We always encourage you to reach your own conclusions though. So sense check these analyst numbers against your own assumptions and expectations based on your understanding of the business and what you believe is probable.